1-4 of 4
Mitsuharu Hashimura, MD
Close
Sort by
Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Manabu Hirai, MDPhD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, MD PhD, Erina Sakamoto, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1688.
https://doi.org/10.1182/blood.V126.23.1688.1688
Published: 2015
Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Manabu Hirai, MDPhD, Mizuki Aimoto, MD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Erina Sakamoto, MD PhD, Hirohisa Nakamae, Masayuki Hino, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3260.
https://doi.org/10.1182/blood.V124.21.3260.3260
Published: 2014
Journal Articles

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Manabu Hirai, MD, PHD, Takahiko Nakane, M.D., Ph.D., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, M.D., Erina Sakamoto, MD, PHD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1536.
https://doi.org/10.1182/blood.V122.21.1536.1536
Published: 2013
Journal Articles

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Manabu Hirai, MD, PHD, Ryousuke Yamamura, MD, PHD, Hirohisa Nakamae, MD, PhD, Yoshiki Terada, MD., PhD., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Hiroyoshi Ichihara, MD, PHD, Erina Sakamoto, MD, PHD, Masayuki Hino
Journal: Blood
Blood (2012) 120 (21): 1187.
https://doi.org/10.1182/blood.V120.21.1187.1187
Published: 2012